Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery
Randomized Phase II Trial of Adjuvant Combined Epigenetic Therapy With 5-Azacitidine and Entinostat in Resected Stage I Non-small Cell Lung Cancer Versus Standard Care
研究概览
详细说明
PRIMARY OBJECTIVES:
I. To assess the effect of 5-azacitidine and entinostat on the hazard of 3 year progression-free survival in patients with resected stage I non-small cell lung cancer.
SECONDARY OBJECTIVES:
I. To assess the safety, tolerability and toxicity of entinostat and 5-azacitidine in patients with resected stage I non-small cell lung cancer.
II. To explore the effect of entinostat and 5-azacitidine on median disease-free and overall survival in patients with resected stage I non-small cell lung cancer.
III. To assess the pharmacodynamic effects of 5-azacitidine and entinostat on DNA methylation and gene re-expression in patients with resected stage I NSCLC through analysis of sputum.
IV. To estimate the effect of entinostat and 5-azacitidine on progression free survival comparing patients with N2 lymph nodes categorized as methylated pre-treatment with those who are categorized as unmethylated.
V. To establish factors that predict clinical outcome in patients treated with combination epigenetic therapy by performing genome-wide analyses on pre-treatment tumor DNA.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive azacitidine subcutaneously (SC) on days 1-5 and 8-10 and entinostat orally (PO) once daily (QD) on days 3 and 10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive standard of care.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
California
-
Los Angeles、California、美国、90033
- USC / Norris Comprehensive Cancer Center
-
-
Florida
-
Tampa、Florida、美国、33612
- Moffitt Cancer Center
-
-
Maryland
-
Annapolis、Maryland、美国、21401
- Anne Arundel Medical Center
-
Baltimore、Maryland、美国、21204
- Greater Baltimore Medical Center
-
Baltimore、Maryland、美国、21224
- Johns Hopkins Bayview Medical Center
-
Baltimore、Maryland、美国、21231
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15232
- University of Pittsburgh Cancer Institute
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Dallas、Texas、美国、75390
- University of Texas Southwestern Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients must be status post complete (R0) surgical resection of pathologically-proven NSCLC (stage IA-IB according to AJCC version 7)
- Patients must be at least 4 weeks out from completion of surgery
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Absolute neutrophil count >= 1,000/mcL
- Platelets >= 100,000/mcL
- Total bilirubin =< 1.5 X institutional upper limit of normal
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
- Creatinine =< 1.5 X institutional upper limit of normal
- The effects of entinostat and 5-azacitidine on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients must be within 8 weeks of completing surgery
- Patients who have received prior chemotherapy or radiation for treatment of their current diagnosis of lung cancer
- Patients with sub-lobar resections (ie: wedge resection or segmentectomy)
- Patients without mediastinal lymph node specimens from mediastinoscopy or surgery (at least level R4 or 7 for right sided tumors OR at least level 5, 6 or 7 for left sided tumors)
- Patients may not be receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat, 5-azacitidine or other agents used in the study
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because entinostat and 5-azacitidine are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with entinostat or 5-azacitidine, breastfeeding should be discontinued if the mother is treated on this protocol; these potential risks may also apply to other agents used in this study
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with entinostat or 5-azacitidine; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Arm I (azacitidine, entinostat)
Patients receive azacitidine SC on days 1-5 and 8-10 and entinostat PO QD on days 3 and 10.
Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
|
相关研究
给定采购订单
其他名称:
鉴于SC
其他名称:
|
无干预:Arm II (standard of care)
Patients receive standard of care.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Disease-free Survival (DFS)
大体时间:3 years
|
The DFS hazard rate and 95% confidence interval will be reported.
At this time, event time distributions for disease-free survival in the two arms will be estimated with the method of Kaplan and Meier and compared using a stratified Cox-proportional hazards model (stratified for stage IA vs IB) with a two-sided alpha of 10%.
|
3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Factors That Predict Clinical Outcome in Patients Treated With Combination Epigenetic Therapy in Terms of Epigenomic Data Generated From the Illumina Platform
大体时间:Up to 2 years
|
The study was terminated early due to poor accrual since the requirement of clinic administration of the 5AZA daily and post-operative patients not wanting 6 months of treatment.
For this reason, 13 pts were enrolled and data was not analyzed, for which we are unable to make any conclusions or report results.
|
Up to 2 years
|
Median Disease-free Survival
大体时间:Up to 5 years
|
Determined by the method determined by Kaplan and Meier.
Estimated with 95% confidence intervals.
Cox proportional hazard modeling will be used for multivariate analysis.
|
Up to 5 years
|
Number of Relapses and Deaths Per Total Time of Follow-up Comparing Patients With N2 Lymph Nodes in Terms of Methylated and Unmethylated
大体时间:Up to 5 years
|
Kaplan Meier curves will be used.
|
Up to 5 years
|
Overall Survival
大体时间:Up to 5 years
|
Determined by the method determined by Kaplan and Meier.
Estimated with 95% confidence intervals.
Cox proportional hazard modeling will be used for multivariate analysis.
|
Up to 5 years
|
Presence of Methylation Patterns
大体时间:Up to 2 years
|
McNemar's test will be used to compare the change in methylation after treatment in sputum.
|
Up to 2 years
|
Toxicities Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0
大体时间:Up to 5 years
|
Simple descriptive statistics will be utilized to display the data.
|
Up to 5 years
|
合作者和调查者
调查人员
- 首席研究员:Charles Rudin、Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- NCI-2012-02901 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- P30CA006973 (美国 NIH 拨款/合同)
- NA_00038631
- J1037 (其他标识符:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital)
- 8311 (其他标识符:CTEP)
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
实验室生物标志物分析的临床试验
-
ORIOL BESTARD完全的
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)尚未招聘艾滋病毒感染 | 乙型肝炎
-
Hvidovre University HospitalElsassFonden终止
-
Fundació Sant Joan de DéuStanley Medical Research Institute; Parc Sanitari Sant Joan de Déu; Hospital Sant Joan de Deu完全的